Regulatory Gap Assessment

Overview

Regulatory gaps can arise from incomplete dossiers, outdated approvals, inconsistent product information, missed commitments, unassessed changes, or differences between current operations and approved regulatory documentation.

Mediature GxP Solutions Pvt. Ltd. (MGS) provides regulatory gap assessments for pharmaceutical, biopharmaceutical, medical-device, and other regulated organizations to help identify areas requiring corrective action or stronger regulatory control.

Our approach evaluates the current regulatory status, supporting documentation, product lifecycle activities, and applicable market requirements to provide a clear view of compliance risks and improvement priorities.

Our Regulatory Gap Assessment Services

Dossier Gap Assessment

Review of dossier content to identify missing, outdated, inconsistent, or insufficient technical and regulatory information.

Submission Readiness Assessment

Evaluation of the completeness and consistency of documentation before regulatory submission.

Registration Status Review

Assessment of existing registrations, approvals, licenses, and renewal status across applicable markets.

Regulatory Commitment Review

Evaluation of open commitments, post-approval obligations, pending actions, and regulatory due dates.

Change Impact Gap Assessment

Review of operational or technical changes to determine whether corresponding regulatory actions have been appropriately assessed or completed.

Labelling & Product Information Gap Assessment

Comparison of current labels, inserts, artwork, and product information against approved documentation.

Lifecycle Management Gap Assessment

Assessment of variation, renewal, dossier-maintenance, and regulatory tracking processes.

Regulatory Process & Governance Assessment

Review of internal procedures, responsibilities, trackers, escalation mechanisms, and document-control practices supporting regulatory activities.

Key Areas We Assess

Depending on the scope, MGS may review:

• Product registrations
• Marketing authorizations
• Regulatory dossiers
• CTD/eCTD content
• Submission history
• Regulatory correspondence
• Authority commitments
• Variations and amendments
• Renewals
• Manufacturing-site information
• Specifications
• Analytical documentation
• Validation information
• Stability documentation
• Labelling and artwork
• Safety-related updates
• Regulatory change control
• Product lifecycle records
• Regulatory trackers
• SOPs and governance
• Document control

Our Approach

01 — Define the Scope

Understand the product, market, regulatory history, current status, and assessment objective.

02 — Review Documentation

Evaluate available approvals, dossiers, submissions, correspondence, trackers, and supporting records.

03 — Identify Gaps

Highlight missing information, inconsistencies, overdue actions, uncontrolled changes, and areas of regulatory risk.

04 — Prioritize

Rank gaps according to their potential impact on submission readiness, approval status, compliance, and business continuity.

05 — Develop an Action Plan

Define corrective actions, responsibilities, priorities, timelines, and required supporting documentation.

06 — Support Remediation

Where required, assist with document updates, tracker improvement, lifecycle actions, and follow-up review.

Deliverables

Depending on scope, MGS can provide:

• Regulatory gap-assessment report
• Dossier-gap tracker
• Registration-status review
• Commitment tracker review
• Lifecycle-gap summary
• Risk-prioritized action plan
• Remediation roadmap
• Regulatory process improvement recommendations
• Follow-up assessment
• Management summary

Why Choose MGS

Integrated Regulatory Review

MGS assesses regulatory gaps with consideration of quality, manufacturing, validation, safety, and technical documentation.

Risk-Based Prioritization

Findings are prioritized according to their potential regulatory and business impact.

Practical Remediation

Recommendations are designed to help clients move from gap identification to clear corrective actions.

Lifecycle Perspective

Our assessment covers not only initial submissions but also post-approval maintenance, changes, renewals, and ongoing commitments.

Independent Perspective

An external review can help identify regulatory weaknesses that may not be visible during routine internal activities.

Who We Support

MGS can provide regulatory gap assessments for:

• Pharmaceutical companies
• API manufacturers
• Finished dosage form organizations
• Biopharmaceutical companies
• Medical-device organizations
• Marketing Authorization Holders
• Product developers
• Contract manufacturers
• Start-ups and expanding organizations